■偏头痛给全球带来了巨大的负担,影响患者和社会。药物治疗,作为主要治疗方法,引起特定的不良反应。强调这些反应对于改善治疗策略和提高患者的幸福感至关重要。因此,我们对相关文献进行了全面的文献计量和可视化分析。
■我们对在WebofScience中扩展的科学引文索引进行了全面搜索,根据文档类型等标准限制分析文献,出版日期,和语言。随后,我们利用了各种分析工具,包括VOSviewer,ScimagoGraphica,R包\'Bibliometrix\',CiteSpace,和Excel程序,为了对期刊数据进行细致的检查和系统的组织,作者,国家/地区,机构,关键词,和参考。
■到2023年8月31日,文献分布在全球379种期刊上,由1726个机构的4235个人撰写。它包含2,363个关键字和38,412个引用。\'HEADACHE\'在出版物计数中领先,与\'SILBERSTEINS\'作为最多产的作者。美国在出版物数量上排名最高,与“UNIV哥本哈根”在机构中处于领先地位。
■我们的研究结果表明,该领域的研究人员继续关注降钙素基因相关肽(CGRP)系统,并通过应用新的生物技术方法探索药物开发的多种机制。此外,必须加强对临床试验结果的评估,持续监测主要药物如Erenumab和Fremanezumab的疗效和安全性.需要进一步评估针对不同人群和不同类型的偏头痛定制的急性和预防性治疗。
UNASSIGNED: Migraine imposes a substantial global burden, impacting patients and society. Pharmacotherapy, as a primary treatment, entails specific
adverse reactions. Emphasizing these reactions is pivotal for improving treatment strategies and enhancing patients\' well-being. Thus, we conducted a comprehensive bibliometric and visual analysis of relevant literature.
UNASSIGNED: We conducted a comprehensive search on the Science Citation Index Expanded within the Web of Science, restricting the literature for analysis based on criteria such as document type, publication date, and language. Subsequently, we utilized various analytical tools, including VOSviewer, Scimago Graphica, the R package \'bibliometrix\', CiteSpace, and Excel programs, for a meticulous examination and systematic organization of data concerning journals, authors, countries/regions, institutions, keywords, and references.
UNASSIGNED: By August 31, 2023, the literature was distributed across 379 journals worldwide, authored by 4,235 individuals from 1726 institutions. It featured 2,363 keywords and 38,412 references. \'HEADACHE\' led in publication count, with \'SILBERSTEIN S\' as the most prolific author. The United States ranked highest in publication volume, with \'UNIV COPENHAGEN\' leading among institutions.
UNASSIGNED: Our research findings indicate that researchers in the field continue to maintain a focus on the calcitonin gene-related peptide (CGRP) system and explore diverse mechanisms for drug development through the application of novel biotechnological approaches. Furthermore, it is imperative to enhance the assessment of clinical trial outcomes, consistently monitor the efficacy and safety of prominent drugs such as Erenumab and Fremanezumab. There is a need for further evaluation of acute and preventive treatments tailored to different populations and varying types of migraine.